STAT5BN642H is a driver mutation for T cell neoplasia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Signal transducer and activator of transcription 5B (STAT5B) mutations are implicated in hematopoietic malignancies.
• The Asp642His (N642H) STAT5B mutation is frequently observed in leukemia and lymphoma patients.

Purpose of the Study:

• To investigate the oncogenic potential of the STAT5BN642H mutation in vivo.
• To identify therapeutic targets for STAT5BN642H-driven hematologic cancers.

Main Methods:

• Generation of transgenic mouse models expressing wild-type STAT5B or the STAT5BN642H mutant in hematopoietic cells.
• Analysis of hematopoietic phenotypes, tumor development, gene expression, and DNA methylation patterns.
• Assessment of sensitivity to JAK and Aurora kinase inhibitors.

Main Results:

• STAT5BN642H expression in mice led to rapid development of transplantable CD8+ T cell lymphoma and leukemia.
• The mutation caused persistent STAT5BN642H tyrosine phosphorylation, altered gene expression, and DNA methylation changes.
• STAT5BN642H-driven T cell neoplasms were sensitive to JAK and Aurora kinase inhibitors.

Conclusions:

• The STAT5BN642H mutation is a driver of T cell lymphoma and leukemia.
• Targeting JAK and Aurora kinases represents a promising therapeutic strategy for patients with STAT5BN642H-mutated hematologic malignancies.